VENOUS ETHANOL ABLATION IN ISCHEMIC VENTRICULAR TACHYCARDIA- VELVET TRIAL

静脉乙醇消融治疗缺血性室性心动过速 - VELVET 试验

基本信息

批准号：
10663024
负责人：
Miguel Valderrabano
金额：
$ 73.83万
依托单位：
METHODIST HOSPITAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10663024
关键词：
Ablation Adhesions Adrenergic Agents Anatomy Angiography Area Arteries Atherosclerosis Authorization documentation Cannulations Cardiac Cardiac ablation Cardiomyopathies Case Study Catheterization Characteristics Cicatrix Circulation Clinical Clinical Trials Collection Contracts Coronary Coronary Vessels Coronary artery Coronary sinus structure Data Denervation Embryology Enrollment Ethanol Fatty acid glycerol esters Future Goals Heart Hypersensitivity Image Infarction Infusion procedures Investigational Drugs Ischemia Left Lesion Magnetic Resonance Manuals Maps Multimodal Imaging Myocardial Myocardial Infarction Myocardial Ischemia Myocardium Nerve Outcome Patients Pericardial body location Phase Play Positron-Emission Tomography Procedures Protocols documentation Radiofrequency Interstitial Ablation Randomized Refractory Registries Research Personnel Risk Role Route Safety Site Structure Structure of left gastric vein Structure of phrenic nerve Techniques Testing Therapeutic Therapeutic Effect Tracer Veins Venous Ventricular Ventricular Arrhythmia Ventricular Premature Complexes Ventricular Tachycardia Work authority cardiac magnetic resonance imaging clinical efficacy clinical trial protocol design experience improved injured insight ischemic cardiomyopathy nerve supply operation radio frequency randomized trial randomized, clinical trials structural determinants success

项目摘要

Abstract Radiofrequency (RF) ablation of ventricular tachycardia (VT) in ischemic cardiomyopathy is fraught with limitations due to suboptimal efficacy, risk of complications, and frequent need for repeat procedures. Ischemic VT arises as a result of reentrant circuits within or around the myocardial scar of an infarct. The co-localization of ventricular arteries, veins, and nerves, is an anatomical fact, determined by the embryology of coronary vessels. Just as myocardial infarctions have a “culprit” or “infarct-related artery”, there commonly exists an “infarct-related vein” or veins in VT substrate. Additionally, it is well known that autonomic innervation -in anatomical proximity to the veins- plays an important role in post-MI arrhythmogenesis. We have developed an approach to target ablation-refractory VTs via ethanol delivery in the coronary veins that provide venous return from arrhythmogenic sites (venous ethanol, VE). Beyond an initial set of case reports, we have validated the utility of VE in a large, multinational registry, in which we establish the safety and efficacy of VE in RF-refractory VT. Given the co-localization of epicardial arteries, veins and nerves, VE may be particularly suited to impact infarct innervation. Thus, a central goal of this proposal is to capitalize on the presence of coronary veins on the epicardial aspect of a myocardial scar as a therapeutic opportunity of unique mechanisms. We hypothesize that VE added to conventional catheter ablation improves the results of VT ablation. We propose a single-site, investigator-initiated clinical trial on VE. In Aim 1-R61 phase-, we propose to finalize the design of randomized clinical trial to assess the clinical efficacy, and safety of VE when used in combination with RF ablation compared with RF ablation alone -Venous Ethanol for Left Ventricular Ischemic VEntricular Tachycardia -VELVET clinical trial. The trial will include an investigational new drug (IND) authorization by the FDA. Patients with ischemic VT will be randomized to conventional endocardial ablation alone, vs combined with VE in the infarct-related vein. In Aim 2 -R33 phase- we will enroll a total of 156 patients, and collect efficacy, safety and procedural data on the impact of VE added to catheter ablation. This trial will allow for a wealth of new imaging data to be collected that will characterize the extent of myocardial scar and innervation before and after VE -compared to endocardial RF alone. In Aim 3 -R33 phase- we will collect multi-modality imaging data characterizing the VT substrate before and after ablation -with catheter ablation alone vs combined with VE. Cardiac magnetic resonance, venous CT angiograms and regional adrenergic innervation maps with positron emission tomography (PET) scans of innervation tracers (11C hydroxyephedrine, 11C-HED) will provide a complete structural assessment of the VT substrate, before and after ablation. If completed, the project will validate a new procedural strategy and will provide key new insights into the structural determinants of VT ablation success.

抽象的缺血性心肌病室性心动过速 (VT) 的射频 (RF) 消融充满了由于疗效欠佳、并发症风险以及频繁需要重复手术而造成的局限性而导致缺血。 VT 是由梗死心肌疤痕内或周围的折返回路引起的。心室动脉、静脉和神经的组成，是一个解剖学事实，由冠状动脉的胚胎学决定正如心肌梗塞有一个“罪魁祸首”或“梗塞相关动脉”一样，通常也存在一个血管。 “梗塞相关静脉”或 VT 基质中的静脉此外，众所周知，自主神经支配。与静脉的解剖学接近度在心肌梗死后心律失常发生中起着重要作用。通过在冠状静脉中输送乙醇提供静脉回流来实现目标消融难治性室性心动过速的方法除了最初的一组病例报告外，我们还验证了来自致心律失常部位（静脉乙醇，VE）的信息。 VE 在大型跨国登记中的实用性，其中我们确定了 VE 在射频难治性患者中的安全性和有效性考虑到心外膜动脉、静脉和神经的共定位，VE 可能特别适合影响。因此，该提案的中心目标是利用冠状静脉的存在。心肌疤痕的心外膜方面作为独特机制的治疗机会。传统导管消融中添加 VE 可改善 VT 消融的效果。研究者发起的 VE 临床试验。在Aim 1-R61阶段-，我们建议完成随机临床试验的设计以评估临床疗效，与单独射频消融相比，VE 与射频消融联合使用时的安全性 - 静脉乙醇左心室缺血性室性心动过速 -VELVET 临床试验将包括一项。 FDA 批准的研究性新药 (IND) 患者将被随机分配至缺血性 VT 患者。单独传统心内膜消融与梗死相关静脉中联合 VE 比较。在目标 2 -R33 阶段 - 我们将总共招募 156 名患者，并收集以下方面的疗效、安全性和程序数据：该试验将收集大量新的成像数据。与心内膜相比，这将表征 VE 前后心肌疤痕和神经支配的程度仅 RF。在 Aim 3 -R33 阶段 - 我们将收集表征 VT 基底的多模态成像数据。以及消融后 - 单独导管消融与联合 VE。血管造影和区域肾上腺素神经支配图与正电子发射断层扫描（PET）扫描神经支配示踪剂（11C 羟基麻黄碱、11C-HED）将提供 VT 的完整结构评估基板，烧蚀之前和之后。如果完成，该项目将验证新的程序策略，并将提供有关 VT 消融成功的结构决定因素。